Methylmalonic Acidemia Market

DelveInsight’s Methylmalonic Acidemia Report delivers an in-depth understanding of the Methylmalonic Acidemia, historical and forecasted epidemiology, and the Methylmalonic Acidemia market trends in the United States EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some Crucial Highlights from the Methylmalonic Acidemia Market Report

• According to the research “Systematic literature review and meta-analysis on the epidemiology of Methylmalonic Acidemia (MMA) with an emphasis on MMA caused by methylmalonyl-CoA mutase (mut) deficiency” by Almási et al. (2019), the Meta-analysis pooled point estimates of MMA detection rates in Asia-Pacific, Europe, North America, and Middle East and North Africa (MENA) were 0.79, 1.12, 1.22, and 6.04 per 100,000 newborns.

• Pipeline therapies in the Methylmalonic Acidemia are LB-001 (LogicBio Therapeutics), HST5040 (HemoShear Therapeutics), and others.

• Major players involved in the Methylmalonic Acidemia market are LogicBio Therapeutics, HemoShear Therapeutics, among others.

For more information request sample @ Methylmalonic Acidemia Market

The Methylmalonic Acidemia market report covers existing clinical practices, new drugs, individual therapies’ market share, and current and forecasted Methylmalonic Acidemia market sizes in the 7MM (the United States, the EU5, Germany, Italy, Spain, and France), and Japan.

Methylmalonic Acidemia: Disease Overview

Methylmalonic Acidemia (MMA) is a form of “metabolic inborn error of metabolism” that is inherited. The body is unable to adequately digest or break down certain proteins and fats (lipids) from the food eaten in this state. 

Decompensation incidents, also known as metabolic crises, result from a build-up of toxic compounds and episodes of severe illness. If a metabolic crisis is not addressed, the patient can experience breathing difficulties, seizures, a stroke, a coma, and even death.

Methylmalonic Acidemia Epidemiology Segmentation

• Methylmalonic Acidemia Total Incident Cases

• Methylmalonic Acidemia Incident Cases Based on Mutation in Genes

• Methylmalonic Acidemia Treatable Cases

Methylmalonic Acidemia Treatment Landscape

Vitamin B12 responsiveness is the primary treatment for MMA patients. A low-protein diet food plan is another treatment option for the patient. Aside from that, organ transplantation is the most effective and efficient choice.

Methylmalonic Acidemia Market

The market dynamics of Methylmalonic Acidemia (MMA) are expected to shift in the coming years due to the approval of Carbaglu and a rise in the incidence of MMA, as well as the expected launch of emerging therapies such as LB-001 (LogicBio’s GeneRide technology) and HST5040 (HemoShear Therapeutics), which are expected to boost the market in the forecasted period (2021-2030).

To learn more visit, Methylmalonic Acidemia Market Size

Methylmalonic Acidemia Pipeline Therapies and Major Companies

• LB-001: LogicBio Therapeutics

• HST5040: HemoShear Therapeutics

Table of Contents

Get in touch with our Business executive @ Methylmalonic Acidemia Market Outlook to know more 

Related Reports

Argininosuccinic Aciduria (ASA) Market

Get comprehensive historical and forecast analysis of Argininosuccinic Aciduria (ASA) Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Horizon Therapeutics, Acer Therapeutics, Evox Therapeutics, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/